

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

DISCLOSABLE TRANSACTION PURCHASE OF WEALTH MANAGEMENT PRODUCT

PURCHASE OF WEALTH MANAGEMENT PRODUCT

At the 36th meeting held by the second session of the Board on March 27, 2026, a resolution regarding cash management using self-owned funds was considered and approved, pursuant to which the Company may purchase wealth management products using part of idle self-owned funds of not more than RMB2,500.0 million.

As disclosed in the announcement of the Company dated May 14, 2026, on May 14, 2026, the Company entered into the OCBC Wealth Management Product Agreement No. 1 with OCBC, pursuant to which the Company agreed to purchase wealth management product of an amount of US\$70.0 million from OCBC using idle self-owned funds.

The Board announces that on August 18, 2026, the Company further entered into the OCBC Wealth Management Product Agreement No. 2 with OCBC, pursuant to which the Company agreed to purchase wealth management product of an amount of US\$30.0 million from OCBC using idle self-owned funds.

LISTING RULES IMPLICATIONS

Since the Company entered into the OCBC Wealth Management Product Agreements with OCBC on May 14, 2026 and August 18, 2026, respectively, the transactions contemplated under the OCBC Wealth Management Product Agreement No.1 and the OCBC Wealth Management Product Agreement No. 2 are transactions with the same financial institution which are similar in nature within a 12-month period. For the purpose of computing the relevant percentage ratios under Rule 14.22 of the Listing Rules, such transactions shall be aggregated and treated as if they were one single transaction with such financial institution.

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the OCBC Wealth Management Product Agreements exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management products under the OCBC Wealth Management Product Agreements therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

BACKGROUND

On May 14, 2026, the Company entered into the OCBC Wealth Management Product Agreement No.1 with OCBC, pursuant to which the Company agreed to purchase wealth management product of an amount of US\$70.0 million from OCBC using idle self-owned funds.

The Board announces that on August 18, 2026, the Company further entered into the OCBC Wealth Management Product Agreement No. 2 with OCBC, pursuant to which the Company agreed to purchase wealth management product of an amount of US\$30.0 million from OCBC using idle self-owned funds.

OCBC Wealth Management Product Agreement No. 2

Name of product	:	OCBC Profit-Linked Structured Deposit “Zeng Li” Series Product [Product Code: SH202605150114PLI] (華僑銀行有限公司收益聯結型結構性存款“增利”系列產品[產品代碼SH202605150114PLI])
Type of product	:	Fixed income/Non-principal-guaranteed with floating income
Product risk rating	:	Medium risk
Linked underlying notes	:	USD Bond-linked Notes (Series Number: SD[ID0334])
Principal amount	:	US\$30.0 million
Product subscription date	:	August 18, 2026
Product trading date	:	August 19, 2026
Product investment period	:	The start date of the product is August 24, 2026 and the maturity date is August 20, 2027. In the event of an early redemption, the product shall mature early, and the actual product investment period is subject to the redemption time of the subscriber.
Expected annualized yield rate	:	The performance will fluctuate with the market and is subject to uncertainty.
Provisions on early redemption	:	Subject to the consent of OCBC, the subscriber may redeem the product in full or in part in advance.
Right of early termination	:	OCBC has the right to early terminate the product
Investment scope	:	The product’s proceeds shall be invested in standardized fixed-income assets such as the money market and bond market.

The terms of the OCBC Wealth Management Product Agreement No.2 were determined upon arm’s length negotiations between the parties.

INFORMATION ON THE PARTIES

The Company is a commercial-ready biopharmaceutical company committed to the discovery, development and commercialization of innovative and differentiated biologics for the treatment of autoimmune, oncology and ophthalmic diseases with unmet medical needs in China and globally.

OCBC is a bank incorporated in Singapore, and is also the longest-established local bank in Singapore. It is listed on the Singapore Exchange (Stock Code: O39). Its core businesses include corporate banking, financial institutions business, global financial markets business and private banking business.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, OCBC and its ultimate substantial beneficial owners as publicly disclosed by OCBC are third parties independent from the Company and its connected persons.

REASONS FOR AND BENEFITS OF ENTERING INTO THE OCBC WEALTH MANAGEMENT PRODUCT AGREEMENT NO. 2

On the premise of strictly controlling investment risks, the Company intends to fully revitalize idle funds and improve capital utilization efficiency by deploying and managing idle funds through bank wealth management products. The allocated low – to medium-risk products feature overall controllable risks and yields higher than those of bank time deposits for the same period, which can effectively boost the investment returns on idle funds.

The Directors consider that the terms of the OCBC Wealth Management Product Agreement No. 2 and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better in the ordinary course of business of the Group, and are in the interests of the Company and its Shareholders as a whole.

LISTING RULES IMPLICATIONS

As one of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the OCBC Wealth Management Product Agreements exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of wealth management products under the OCBC Wealth Management Product Agreements therefore constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the reporting and announcement requirements under the Listing Rules.

DEFINITIONS

Unless the context otherwise requires, the following terms used herein have the following meanings:

“Board”	the board of Directors
“Company”	RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司), a company incorporated in the PRC with limited liability, the H shares and A shares of which are listed on the Main Board of the Stock Exchange (stock code: 9995) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688331), respectively
“connected person”	has the meaning ascribed to it under the Listing Rules
“Director(s)”	the director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC” or “China”	the People’s Republic of China excluding, for the purpose of this announcement, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholder(s)”	holder(s) of the shares of the Company
“OCBC”	Oversea-Chinese Banking Corporation Limited, a bank incorporated in Singapore
“OCBC Wealth Management Product Agreements”	OCBC Wealth Management Product Agreement No. 1 and OCBC Wealth Management Product Agreement No. 2
“OCBC Wealth Management Product Agreement No. 1”	the wealth management product agreement entered into between the Company and OCBC dated May 14, 2026 in relation to the purchase of wealth management product in the amount of US\$70.0 million
“OCBC Wealth Management Product Agreement No. 2”	the wealth management product agreement entered into between the Company and OCBC dated August 18, 2026 in relation to the purchase of wealth management product in the amount of US\$30.0 million

“Stock Exchange”

The Stock Exchange of Hong Kong Limited

“USD”

United States dollar, the lawful currency of the United States of America

“%”

percent

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and Executive Director

Yantai, the PRC

August 18, 2026

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Wen Qingkai, Ms. Fang Michelle Yi and Mr. Wang Yuxiao as the executive Directors; Dr. Wang Liqiang as the non-executive Director; and Mr. Song Xiliang, Mr. Huang Guobin and Mr. Chen Yunjin as the independent non-executive Directors.

* For identification purpose only